Pay in 4 interest-free payments of $6.87 Learn more
Ships within 48 hours · Estimated delivery Aug 6 - Aug 11
Dual-targeted and controlled release delivery of doxorubicin to breast adenocarcinoma: In vitro and in vivo studies
Research suggests that the medication, a glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptor agonist, originally developed to manage Type 2 diabetes, may be able to treat a wide range of conditions involving impulse control, like binge eating disorder.But although there may be tantalizing clues for helping patients with unwanted impulses, GLP-1 and GIP inhibitors may not be optimally designed to treat them sufficiently and need further research, according to a case study from the Perelman School of Medicine at the University of Pennsylvania, published today in Nature Medicine
Another drawback to these tests is that other factors, such as inflammation, can cause these biomarkers to be abnormally high
Overuse can lead to potential side effects
Glutathione may also have some antioxidant properties
